Which has higher earnings and valuation, PHVS or PRAX?

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Praxis Precision Medicines N/A N/A -$303.27M -$13.37 N/A

Is PHVS or PRAX more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media favor PHVS or PRAX?

In the previous week, Praxis Precision Medicines had 4 more articles in the media than Pharvaris. MarketBeat recorded 8 mentions for Praxis Precision Medicines and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Praxis Precision Medicines' score of 0.91 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, PHVS or TGTX?

TG Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A TG Therapeutics $616.29M 13.66 $447.18M $2.86 19.22

Is PHVS or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Pharvaris' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% TG Therapeutics 65.95% 88.73% 43.44%

Does the media favor PHVS or TGTX?

In the previous week, TG Therapeutics had 15 more articles in the media than Pharvaris. MarketBeat recorded 19 mentions for TG Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat TG Therapeutics' score of 0.48 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PHVS or CRNX?

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Pharvaris. MarketBeat recorded 8 mentions for Crinetics Pharmaceuticals and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Crinetics Pharmaceuticals' score of 0.19 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, PCVX or PHVS?

Pharvaris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Pharvaris N/A N/A -$198.79M -$3.18 N/A

Is PCVX or PHVS more profitable?

Vaxcyte's return on equity of -32.51% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Pharvaris N/A -67.56% -61.13%

Does the media favor PCVX or PHVS?

In the previous week, Vaxcyte had 2 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Vaxcyte and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Vaxcyte's score of 0.69 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SYRE or PHVS?

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics N/A N/A -$155.20M -$2.08 N/A Pharvaris N/A N/A -$198.79M -$3.18 N/A

Is SYRE or PHVS more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Pharvaris N/A -67.56% -61.13%

Does the media refer more to SYRE or PHVS?

In the previous week, Spyre Therapeutics had 3 more articles in the media than Pharvaris. MarketBeat recorded 7 mentions for Spyre Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Spyre Therapeutics' score of 0.85 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pharvaris (PHVS) Competitors

$33.25 -1.91 (-5.43%)

As of 03:11 PM Eastern

Compare

PHVS vs. PRAX, TGTX, CRNX, PCVX, and SYRE

Should you buy Pharvaris stock or one of its competitors? MarketBeat compares Pharvaris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharvaris include Praxis Precision Medicines (PRAX), TG Therapeutics (TGTX), Crinetics Pharmaceuticals (CRNX), Vaxcyte (PCVX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Pharvaris compare to Praxis Precision Medicines?

Pharvaris (NASDAQ:PHVS) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pharvaris currently has a consensus price target of $50.08, suggesting a potential upside of 50.63%. Praxis Precision Medicines has a consensus price target of $563.50, suggesting a potential upside of 84.99%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Praxis Precision Medicines had 4 more articles in the media than Pharvaris. MarketBeat recorded 8 mentions for Praxis Precision Medicines and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Praxis Precision Medicines' score of 0.91 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines' return on equity of -43.02% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

Summary

Praxis Precision Medicines beats Pharvaris on 9 of the 14 factors compared between the two stocks.

How does Pharvaris compare to TG Therapeutics?

Pharvaris (NASDAQ:PHVS) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

TG Therapeutics has a net margin of 65.95% compared to Pharvaris' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
TG Therapeutics	65.95%	88.73%	43.44%

58.6% of TG Therapeutics shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pharvaris has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
TG Therapeutics	$616.29M	13.66	$447.18M	$2.86	19.22

Pharvaris presently has a consensus price target of $50.08, indicating a potential upside of 50.63%. TG Therapeutics has a consensus price target of $53.33, indicating a potential downside of 3.00%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts plainly believe Pharvaris is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, TG Therapeutics had 15 more articles in the media than Pharvaris. MarketBeat recorded 19 mentions for TG Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat TG Therapeutics' score of 0.48 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TG Therapeutics beats Pharvaris on 10 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Crinetics Pharmaceuticals?

Pharvaris (NASDAQ:PHVS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Pharvaris currently has a consensus price target of $50.08, indicating a potential upside of 50.63%. Crinetics Pharmaceuticals has a consensus price target of $78.27, indicating a potential downside of 6.66%. Given Pharvaris' stronger consensus rating and higher possible upside, equities research analysts plainly believe Pharvaris is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 11.8% of Pharvaris shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pharvaris has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Crinetics Pharmaceuticals	$18.07M	489.33	-$465.32M	-$5.13	N/A

Pharvaris has a beta of -2.34, indicating that its share price is 334% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Pharvaris. MarketBeat recorded 8 mentions for Crinetics Pharmaceuticals and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Crinetics Pharmaceuticals' score of 0.19 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharvaris has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Summary

Pharvaris beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Pharvaris compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Vaxcyte's return on equity of -32.51% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Pharvaris	N/A	-67.56%	-61.13%

Pharvaris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Vaxcyte has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vaxcyte currently has a consensus target price of $86.00, indicating a potential upside of 54.86%. Pharvaris has a consensus target price of $50.08, indicating a potential upside of 50.63%. Given Vaxcyte's higher possible upside, equities analysts clearly believe Vaxcyte is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, Vaxcyte had 2 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Vaxcyte and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Vaxcyte's score of 0.69 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vaxcyte and Pharvaris tied by winning 7 of the 14 factors compared between the two stocks.

How does Pharvaris compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Pharvaris (NASDAQ:PHVS) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Spyre Therapeutics presently has a consensus price target of $101.42, indicating a potential upside of 6.62%. Pharvaris has a consensus price target of $50.08, indicating a potential upside of 50.63%. Given Pharvaris' higher possible upside, analysts plainly believe Pharvaris is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, Spyre Therapeutics had 3 more articles in the media than Pharvaris. MarketBeat recorded 7 mentions for Spyre Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat Spyre Therapeutics' score of 0.85 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, meaning that its share price is 334% less volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Spyre Therapeutics' return on equity of -42.88% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Pharvaris	N/A	-67.56%	-61.13%

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Summary

Spyre Therapeutics beats Pharvaris on 10 of the 13 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export

Metric	Pharvaris	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.18B	$3.67B	$6.85B	$12.46B
Dividend Yield	N/A	2.22%	2.68%	9.44%
P/E Ratio	-10.46	21.00	27.16	24.23
Price / Sales	N/A	175.83	510.03	87.66
Price / Cash	N/A	143.89	48.63	60.03
Price / Book	7.06	8.35	10.78	6.22
Net Income	-$198.79M	$23.83M	$3.59B	$331.94M
7 Day Performance	-7.54%	-5.42%	-2.63%	-1.94%
1 Month Performance	5.69%	5.02%	2.68%	-0.99%
1 Year Performance	44.57%	45.06%	25.02%	18.02%

Pharvaris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHVS Pharvaris	4.3689 of 5 stars	$33.25 -5.4%	$50.08 +50.6%	+52.9%	$2.18B	N/A	N/A	30	News Coverage Positive News Analyst Upgrade
PRAX Praxis Precision Medicines	3.2528 of 5 stars	$323.95 +3.3%	$569.63 +75.8%	+513.6%	$9.03B	$8.55M	N/A	110	Analyst Forecast
TGTX TG Therapeutics	3.0385 of 5 stars	$58.06 +4.7%	$52.17 -10.2%	+48.6%	$8.89B	$616.29M	20.30	290	Trending News Analyst Forecast Analyst Revision
CRNX Crinetics Pharmaceuticals	1.4505 of 5 stars	$83.53 +98.7%	$78.27 -6.3%	+163.6%	$8.81B	$7.70M	N/A	210	High Trading Volume
PCVX Vaxcyte	2.6348 of 5 stars	$60.67 +6.5%	$86.00 +41.8%	+60.8%	$8.76B	N/A	N/A	160	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHVS) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Competitors

PHVS vs. PRAX, TGTX, CRNX, PCVX, and SYRE

How does Pharvaris compare to Praxis Precision Medicines?

Summary

How does Pharvaris compare to TG Therapeutics?

Summary

How does Pharvaris compare to Crinetics Pharmaceuticals?

Summary

How does Pharvaris compare to Vaxcyte?

Summary

How does Pharvaris compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharvaris (PHVS) Competitors

PHVS vs. PRAX, TGTX, CRNX, PCVX, and SYRE

How does Pharvaris compare to Praxis Precision Medicines?

Do institutionals and insiders hold more shares of PHVS or PRAX?

Do analysts rate PHVS or PRAX?

Does the media favor PHVS or PRAX?

Is PHVS or PRAX more profitable?

Which has higher earnings and valuation, PHVS or PRAX?

Which has more risk and volatility, PHVS or PRAX?

Summary

How does Pharvaris compare to TG Therapeutics?

Is PHVS or TGTX more profitable?

Do insiders and institutionals believe in PHVS or TGTX?

Which has more risk and volatility, PHVS or TGTX?

Which has preferable earnings and valuation, PHVS or TGTX?

Do analysts rate PHVS or TGTX?

Does the media favor PHVS or TGTX?

Summary

How does Pharvaris compare to Crinetics Pharmaceuticals?

Do analysts recommend PHVS or CRNX?

Do institutionals & insiders believe in PHVS or CRNX?

Which has stronger valuation & earnings, PHVS or CRNX?

Which has more risk and volatility, PHVS or CRNX?

Does the media prefer PHVS or CRNX?

Is PHVS or CRNX more profitable?

Summary

How does Pharvaris compare to Vaxcyte?

Is PCVX or PHVS more profitable?

Which has stronger earnings and valuation, PCVX or PHVS?

Which has more risk & volatility, PCVX or PHVS?

Do insiders & institutionals believe in PCVX or PHVS?

Do analysts rate PCVX or PHVS?

Does the media favor PCVX or PHVS?

Summary

How does Pharvaris compare to Spyre Therapeutics?

Do analysts recommend SYRE or PHVS?

Does the media refer more to SYRE or PHVS?

Which has more volatility & risk, SYRE or PHVS?

Do institutionals and insiders believe in SYRE or PHVS?

Is SYRE or PHVS more profitable?

Which has better earnings & valuation, SYRE or PHVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools